A citation-based method for searching scientific literature

Katsutoshi Oda, Junzo Hamanishi, Koji Matsuo, Kosei Hasegawa. Gynecol Oncol 2018
Times Cited: 52







List of co-cited articles
476 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
627
44

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
187
28

ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C Wiegand, Sohrab P Shah, Osama M Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, Janine Senz, Melissa K McConechy, Michael S Anglesio, Steve E Kalloger,[...]. N Engl J Med 2010
26

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Siân Jones, Tian-Li Wang, Ie-Ming Shih, Tsui-Lien Mao, Kentaro Nakayama, Richard Roden, Ruth Glas, Dennis Slamon, Luis A Diaz, Bert Vogelstein,[...]. Science 2010
823
19

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
19

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, Alexandra Zimmer, Stanley Lipkowitz, Christina M Annunziata, Liang Cao, Maria I Harrell, Elizabeth M Swisher, Nicole Houston,[...]. J Clin Oncol 2017
140
19

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto, Tetsutaro Hamano, Eriko Aotani, Yasuhisa Terao, Nao Suzuki, Mikio Mikami, Nobuo Yaegashi, Kiyoko Kato,[...]. J Clin Oncol 2016
73
19

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
151
19

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Kuan-Ting Kuo, Tsui-Lien Mao, Siân Jones, Emanuela Veras, Ayse Ayhan, Tian-Li Wang, Ruth Glas, Dennis Slamon, Victor E Velculescu, Robert J Kuman,[...]. Am J Pathol 2009
297
17

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
17

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund,[...]. Lancet Oncol 2012
537
15

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Brooke E Howitt, Kyle C Strickland, Lynette M Sholl, Scott Rodig, Lauren L Ritterhouse, Dipanjan Chowdhury, Alan D D'Andrea, Ursula A Matulonis, Panagiotis A Konstantinopoulos. Oncoimmunology 2017
57
15

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
Panagiotis A Konstantinopoulos, William E Brady, John Farley, Amy Armstrong, Denise S Uyar, David M Gershenson. Gynecol Oncol 2018
23
34

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson. Gynecol Oncol 2018
27
29



Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Brian C Willis, Emily A Sloan, Kristen A Atkins, Mark H Stoler, Anne M Mills. Mod Pathol 2017
31
22


Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Seiji Mabuchi, Toru Sugiyama, Tadashi Kimura. J Gynecol Oncol 2016
62
13

Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Ronald L Chandler, Jeffrey S Damrauer, Jesse R Raab, Jonathan C Schisler, Matthew D Wilkerson, John P Didion, Joshua Starmer, Daniel Serber, Della Yee, Jessie Xiong,[...]. Nat Commun 2015
165
13

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
John K Chan, Deanna Teoh, Jessica M Hu, Jacob Y Shin, Kathryn Osann, Daniel S Kapp. Gynecol Oncol 2008
266
13

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
13

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Ignace Vergote, Claes G Tropé, Frédéric Amant, Gunnar B Kristensen, Tom Ehlen, Nick Johnson, René H M Verheijen, Maria E L van der Burg, Angel J Lacave, Pierluigi Benedetti Panici,[...]. N Engl J Med 2010
13

Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Se Ik Kim, Ji Won Lee, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Jeong-Sun Seo. Gynecol Oncol 2018
41
14


An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Kate E Oliver, William E Brady, Michael Birrer, David M Gershenson, Gini Fleming, Larry J Copeland, Krishnansu Tewari, Peter A Argenta, Robert S Mannel, Angeles Alvarez Secord,[...]. Gynecol Oncol 2017
36
16

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
Hiroaki Itamochi, Tetsuro Oishi, Nao Oumi, Satoshi Takeuchi, Kosuke Yoshihara, Mikio Mikami, Nobuo Yaegashi, Yasuhisa Terao, Kazuhiro Takehara, Kimio Ushijima,[...]. Br J Cancer 2017
38
15

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
696
11

Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis.
Yoriko Yamashita, Shinya Akatsuka, Kanako Shinjo, Yasushi Yatabe, Hiroharu Kobayashi, Hiroshi Seko, Hiroaki Kajiyama, Fumitaka Kikkawa, Takashi Takahashi, Shinya Toyokuni. PLoS One 2013
56
11

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.
Allen W Zhang, Andrew McPherson, Katy Milne, David R Kroeger, Phineas T Hamilton, Alex Miranda, Tyler Funnell, Nicole Little, Camila P E de Souza, Sonya Laan,[...]. Cell 2018
138
11

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng, Peter Mottram, Melina Evdemon-Hogan, Jose R Conejo-Garcia, Lin Zhang, Matthew Burow,[...]. Nat Med 2004
11


Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia,[...]. Nat Med 2015
364
11

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Aikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, Noriomi Matsumura, Hiroyuki Nomura, Hiroaki Itamochi, Masashi Takano, Tadao Takano, Nobuyuki Susumu, Daisuke Aoki,[...]. Int J Gynecol Cancer 2014
76
11

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.
M Takano, Y Kikuchi, N Yaegashi, K Kuzuya, M Ueki, H Tsuda, M Suzuki, J Kigawa, S Takeuchi, H Tsuda,[...]. Br J Cancer 2006
187
11

Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Shinichi Komiyama, Kazuyoshi Kato, Yuki Inokuchi, Hirokuni Takano, Takashi Matsumoto, Atsushi Hongo, Mikiko Asai-Sato, Atsushi Arakawa, Shoji Kamiura, Tsutomu Tabata,[...]. Int J Clin Oncol 2019
26
23

Clear-cell carcinoma of the ovary.
K Fujiwara, D Shintani, T Nishikawa. Ann Oncol 2016
38
15

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
11

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W P McGuire, W J Hoskins, M F Brady, P R Kucera, E E Partridge, K Y Look, D L Clarke-Pearson, M Davidson. N Engl J Med 1996
11

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Joyce F Liu, Christina Herold, Kathryn P Gray, Richard T Penson, Neil Horowitz, Panagiotis A Konstantinopoulos, Cesar M Castro, Sarah J Hill, Jennifer Curtis, Weixiu Luo,[...]. JAMA Oncol 2019
56
11

Cancer-Associated Mutations in Endometriosis without Cancer.
Michael S Anglesio, Nickolas Papadopoulos, Ayse Ayhan, Tayyebeh M Nazeran, Michaël Noë, Hugo M Horlings, Amy Lum, Siân Jones, Janine Senz, Tamer Seckin,[...]. N Engl J Med 2017
257
9

Endometriosis-associated Ovarian Cancers.
Michael S Anglesio, Paul J Yong. Clin Obstet Gynecol 2017
30
16

PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Sohei Yamamoto, Hitoshi Tsuda, Masashi Takano, Keichi Iwaya, Seiichi Tamai, Osamu Matsubara. J Pathol 2011
101
9

Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Kristin K Zorn, Tomas Bonome, Lisa Gangi, Gadisetti V R Chandramouli, Christopher S Awtrey, Ginger J Gardner, J Carl Barrett, Jeff Boyd, Michael J Birrer. Clin Cancer Res 2005
274
9

Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Catherine A Shu, Qin Zhou, Anjali R Jotwani, Alexia Iasonos, Mario M Leitao, Jason A Konner, Carol A Aghajanian. Gynecol Oncol 2015
40
12

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.
Michael L Friedlander, Kenneth Russell, Sherri Millis, Zoran Gatalica, Ryan Bender, Andreas Voss. Int J Gynecol Cancer 2016
45
11

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Vivian Goodell, Lupe G Salazar, Nicole Urban, Charles W Drescher, Heidi Gray, Ron E Swensen, Martin W McIntosh, Mary L Disis. J Clin Oncol 2006
109
9

TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Katia Schlienger, Christina S Chu, Edward Y Woo, Patricia M Rivers, Alanna J Toll, Brian Hudson, Marcela V Maus, James L Riley, Yongwon Choi, George Coukos,[...]. Clin Cancer Res 2003
80
9

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
9

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
Hiroaki Itamochi, Junzo Kigawa, Naoki Terakawa. Cancer Sci 2008
171
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.